• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?

作者信息

Mori Keiichiro, Schmidinger Manuela, Egawa Shin, Gust Kilian M, Shariat Shahrokh F

机构信息

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

出版信息

Eur Urol. 2021 Apr;79(4):e113-e114. doi: 10.1016/j.eururo.2021.01.012. Epub 2021 Jan 21.

DOI:10.1016/j.eururo.2021.01.012
PMID:33487477
Abstract
摘要

相似文献

1
Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复约翰娜·诺埃尔、奥利维耶·于利亚尔和弗朗索瓦·戈德瓦塞尔致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人的《程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析》。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006。免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e113-e114. doi: 10.1016/j.eururo.2021.01.012. Epub 2021 Jan 21.
2
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔菲等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.10.006：免疫检查点抑制剂的临床活性：宿主是答案吗？
Eur Urol. 2021 Apr;79(4):e112. doi: 10.1016/j.eururo.2021.01.013. Epub 2021 Jan 29.
3
Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复高晓帅、陈果和魏鑫致编辑的信，信的内容涉及：森英一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等人。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79卷：783 - 92页
Eur Urol. 2021 Dec;80(6):e145-e146. doi: 10.1016/j.eururo.2021.09.013. Epub 2021 Sep 25.
4
Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.回复：森庆一郎、穆罕默德·阿布法拉吉、哈迪·莫斯塔法埃伊等。程序性死亡配体1在接受免疫检查点抑制剂治疗的转移性肾细胞癌患者中的预测价值：一项系统评价和荟萃分析。《欧洲泌尿外科杂志》2021年；79：783 - 92。
Eur Urol. 2021 Dec;80(6):e143-e144. doi: 10.1016/j.eururo.2021.09.012. Epub 2021 Sep 27.
5
Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.回复尼米什·辛格拉和维塔利·马尔古利斯致编辑的信，信中涉及：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等人。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的手术挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018。肾癌的下一个手术前沿：免疫检查点抑制后的肾切除术：免疫治疗后的肾切除术：治疗暴露时间可能起决定性作用。
Eur Urol. 2020 Aug;78(2):e81-e82. doi: 10.1016/j.eururo.2020.04.052. Epub 2020 May 7.
6
Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.回复：杰拉尔丁·皮尼奥、安托万·蒂埃里 - 维勒明、约亨·瓦尔兹等。转移性肾细胞癌对免疫检查点抑制剂完全缓解后的肾切除术：一项新的外科挑战？《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2019.12.018：肾癌的下一个外科前沿：免疫检查点抑制后的肾切除术
Eur Urol. 2020 Aug;78(2):e79-e80. doi: 10.1016/j.eururo.2020.04.025. Epub 2020 Apr 30.
7
Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.回复赵炳浩、张瑞东和吴佳明致编辑的信，内容涉及：安娜·卡维隆、达米安·普塞尔、纳丁·胡埃德等人。使用互补统计方法评估长期治疗益处：III期KEYNOTE-045和Checkmate-214免疫检查点抑制剂试验的计算机模拟分析。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2023.02.011 。
Eur Urol. 2023 Jul;84(1):e22-e23. doi: 10.1016/j.eururo.2023.04.016. Epub 2023 Apr 27.
8
Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.对希滕·D·帕特尔和穆罕默德·E·阿拉夫致编辑的信的回复，信的主题为：马克辛·孙、安德烈亚斯·贝克尔、田哲等人。局限性肾癌的管理：计算手术和非手术治疗的癌症特异性死亡率及死亡竞争风险。《欧洲泌尿外科杂志》。即将发表。http://dx.doi.org/10.1016/j.eururo.2013.03.034 。
Eur Urol. 2013 Nov;64(5):e107-8. doi: 10.1016/j.eururo.2013.07.025. Epub 2013 Jul 25.
9
Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?回复：比马尔·宾迪、杰弗里·格雷厄姆、J·康纳·韦尔斯等人。初诊转移性肾细胞癌患者的延期减瘤性肾切除术。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2020.04.038：减瘤性肾切除术：适用于谁以及何时进行？
Eur Urol Oncol. 2020 Aug;3(4):559-560. doi: 10.1016/j.euo.2020.05.011. Epub 2020 Jun 15.
10
Reply to Yudai Ishiyama and Fumihiko Urabe's Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006.
Eur Urol. 2024 Dec;86(6):e143-e144. doi: 10.1016/j.eururo.2024.03.016. Epub 2024 Mar 25.